title: HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.
authors.forename: Nadeera
authors.initials: N
authors.lastname: Sidique
authors.forename: Anita
authors.initials: A
authors.lastname: Kohli
authors.forename: Bhavana
authors.initials: B
authors.lastname: Shivakumar
authors.forename: Stephen
authors.initials: S
authors.lastname: Migueles
authors.forename: G Mani
authors.initials: GM
authors.lastname: Subramanian
authors.forename: Susanna
authors.initials: S
authors.lastname: Naggie
authors.forename: Michael A
authors.initials: MA
authors.lastname: Polis
authors.forename: Henry
authors.initials: H
authors.lastname: Masur
authors.forename: Shyam
authors.initials: S
authors.lastname: Kottilil
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000276:immunology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000276:immunology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006678:HIV / Q000502:physiology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology*; D016174:Hepacivirus / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D012189:Retrospective Studies; D012254:Ribavirin / Q000276:immunology / Q000627:therapeutic use; D016896:Treatment Outcome; D014779:Virus Replication / Q000276:immunology*
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a